Ipratropium Bromide And Albuterol Sulfate Solution
Product Images NDC 0487-0201

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Ipratropium Bromide And Albuterol Sulfate (NDC 0487-0201). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nephron Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

B5387e98-figure-01 (B5387e98 Figure 01)

Chemical structure of Ipratropium Bromide, showing its molecular arrangement including functional groups and sulfate ion (H2SO4). The diagram illustrates the compound's structural formula as used in the Ipratropium Bromide and Albuterol Sulfate respiratory solution.*

FDA Label Image

B5387e98-figure-02 (B5387e98 Figure 02)

Chemical structure diagram showing the molecular structure of Ipratropium Bromide, including the trimethylammonium group and a tropane moiety, along with a bromide ion complexed with water (Br-•H2O).*

FDA Label Image

B5387e98-figure-03 (B5387e98 Figure 03)

A line graph showing percent fractional excretion in liters over hours after dosing for three treatments: Albuterol, Ipratropium, and combined Ipratropium Bromide and Albuterol Sulfate inhalation. The graph illustrates the time course of each treatment's excretion profile from 0 to 8 hours post-dose.*

FDA Label Image

B5387e98-figure-04 (B5387e98 Figure 04)

A data table displaying adverse events occurring in more than 1% of patients in treatment groups receiving Albuterol, Ipratropium, or the combination of Ipratropium Bromide and Albuterol Sulfate. It lists the number of patients and percentage experiencing adverse events in body systems including body as a whole, digestive, musculo-skeletal, respiratory, and urogenital. The combination group generally shows the highest percentages across most adverse event categories.*

FDA Label Image

B5387e98-figure-05 (B5387e98 Figure 05)

An instructional diagram demonstrating the preparation of Ipratropium Bromide and Albuterol Sulfate inhalation solution. It shows a vial being attached to a nebulizer device, indicating how the solution is prepared for respiratory inhalation use.*

FDA Label Image

B5387e98-figure-06 (B5387e98 Figure 06)

An instructional diagram showing the assembly or connection of an inhalation device or nebulizer component. The image features a nozzle or mouthpiece being aligned with an airway adapter or tubing connector, illustrating a step for preparing the respiratory inhalation device for use.*

FDA Label Image

B5387e98-figure-07 (B5387e98 Figure 07)

An instructional diagram showing the proper use of an inhalation device. The illustration depicts a person placing the inhaler mouthpiece in their mouth while holding the device with one hand, indicating the correct technique for administering a respiratory solution.*

FDA Label Image

B5387e98-figure-08 (B5387e98 Figure 08)

An instructional illustration showing a person using a respiratory inhalation device. The person is positioning the inhaler near their mouth and pressing the top to release the medication solution for inhalation.*

FDA Label Image

B5387e98-figure-09 (B5387e98 Figure 09)

Label for Ipratropium Bromide 0.5 mg and Albuterol Sulfate 3 mg inhalation solution, a respiratory solution product from Nephron Pharmaceuticals Corporation. The label indicates unit-dose vials of 3 mL each, sold in a pack of five. Storage and usage instructions are provided, along with a barcode and manufacturer contact details.*

FDA Label Image

B5387e98-figure-10 (B5387e98 Figure 10)

Packaging label for Ipratropium Bromide 0.5 mg and Albuterol Sulfate 3 mg inhalation solution by Nephron Pharmaceuticals Corporation. The product is a respiratory inhalation solution supplied in 3 mL sterile unit-dose vials, with the NDC 0487-0201-03. The carton displays dosage strength, usage for oral inhalation only, storage conditions, ingredients, and manufacturer information.*

FDA Label Image

B5387e98 Figure 11

Packaging label for Ipratropium Bromide 0.5 mg and Albuterol Sulfate 3 mg inhalation solution by Nephron Pharmaceuticals Corporation. The label includes dosage form as solution for respiratory inhalation, with a package containing twelve foil pouches each with a 3 mL sterile unit-dose vial. It is indicated for oral inhalation only and is marked Rx only.*

FDA Label Image

B5387e98 Figure 12

Label for Ipratropium Bromide 0.5 mg and Albuterol Sulfate 3 mg inhalation solution from Nephron Pharmaceuticals Corporation. The label specifies the solution is for oral inhalation only and comes in a single 3 mL unit-dose vial. It includes directions for use, storage conditions, and manufacturer contact information, alongside a barcode and lot/expiration placeholders.*

FDA Label Image

B5387e98 Figure 13

Packaging label for Ipratropium Bromide 0.5 mg and Albuterol Sulfate 3 mg inhalation solution. The label displays the product name, strength, and dosage form prominently on a blue background, along with usage instructions for oral inhalation. It indicates a package containing 30 sterile unit-dose vials of 3 mL each, manufactured by Nephron Pharmaceuticals Corporation. The label includes regulatory information, a barcode, and analytical charts on the interior panels.*

FDA Label Image

B5387e98 Figure 14

Packaging label layout for Ipratropium Bromide and Albuterol Sulfate respiratory inhalation solution by Nephron Pharmaceuticals Corporation. The label includes detailed prescribing information panels featuring chemical structures and text, formatted for folding into a carton. Dosage strength indicated as .5 mg/3 mL and 3 mg/3 mL. Manufacturer information appears on the side panel.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.